What is HC Wainwright’s Forecast for INTS FY2026 Earnings?

Intensity Therapeutics Inc. (NASDAQ:INTS) – Equities research analysts at HC Wainwright lowered their FY2026 EPS estimates for shares of Intensity Therapeutics in a report released on Friday, November 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($4.48) for the year, down from their prior forecast of ($1.88). HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($2.64) per share. HC Wainwright also issued estimates for Intensity Therapeutics’ Q4 2026 earnings at ($1.28) EPS, Q1 2027 earnings at ($0.36) EPS, Q2 2027 earnings at ($0.38) EPS, Q3 2027 earnings at ($0.43) EPS, Q4 2027 earnings at ($0.49) EPS and FY2027 earnings at ($1.67) EPS.

A number of other brokerages have also recently weighed in on INTS. Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Monday, October 19th. Citigroup restated a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Intensity Therapeutics Stock Performance

Shares of NASDAQ:INTS opened at $3.15 on Tuesday. Intensity Therapeutics has a 52 week low of $2.80 and a 52 week high of $15.00. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 0.01. The company has a 50 day moving average price of $3.61 and a two-hundred day moving average price of $5.07.

Intensity Therapeutics (NASDAQ:INTS) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.10).

Key Intensity Therapeutics News

Here are the key news stories impacting Intensity Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $7.00 price target, signaling continued analyst support despite its lower earnings forecasts. MarketBeat coverage
• Positive Sentiment: Brookline raised its projected EPS for 2029 to $8.09 from $7.40 and for 2030 to $14.82 from $13.27, suggesting improved expectations for those out-years. MarketBeat coverage
• Negative Sentiment: Both firms cut near-term earnings expectations. HC Wainwright lowered its 2026 EPS forecast to a loss of $4.48 from $1.88 and its 2027 forecast to a loss of $1.67 from $0.92. Brookline also reduced its 2026 and 2027 estimates, to losses of $4.15 and $3.06, respectively. Larger expected losses may pressure the shares. MarketBeat coverage
• Negative Sentiment: Brookline also widened its projected 2028 loss, to $7.32 per share from $6.01, tempering the more optimistic revisions it made for 2029 and 2030. MarketBeat coverage

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc (NASDAQ: INTS) is a clinical-stage biotechnology company developing investigational cancer immunotherapies designed to treat solid tumors. Its approach focuses on injecting therapies directly into tumors to promote tumor-cell destruction and stimulate a broader immune response against cancer.

The company’s lead product candidate, INT230-6, is a proprietary formulation containing the chemotherapy agents cisplatin and vinblastine combined with an amphiphilic delivery agent.